{
    "medicine_id": "c8add0245b57b70139aa77b9448c3d8791a8d844",
    "platform_id": "DB14783",
    "metadata": {
        "name": "Vumerity 231 mg 1 Capsule",
        "composition": "231 mg 1 Diroximel fumarate",
        "clinical_particulars": {
            "therapeutic_indications": "Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis MS in adults specifically active secondary progressive disease and clinically isolated syndrome as well as relapsing remitting MS L9623 L9629 L9632",
            "contraindications": {
                "disease": "Currently an MSDS for diroximel fumarate is unavailable The MSDS for its bioequivalent counterpart dimethyl fumarate indicates an oral LD50 of 2 240 mg kg in rats MSDS There is no information regarding overdose on the FDA label for diroximel fumarate Cases of overdose with its bioequivalent counterpart dimethyl fumarate have been reported in the literature and symptoms reflect the adverse effects of this drug These symptoms include nausea vomiting diarrhea and flushing among others L9632 L8638 Currently there is no antidote to an overdose with diroximel fumarate or dimethyl fumarate Symptomatic and supportive management are the only options up to this date if an overdose should occur L9638",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Diroximel fumarate relieves the neurological symptoms of relapsing MS with less gastrointestinal effects than its bioequivalent counterpart dimethyl fumarate A187532 L9623 It is important to note that diroximel fumarate can cause angioedema anaphylaxis hepatotoxicity flushing lymphopenia and Progressive Multifocal Leukoencephalopathy PML L9623 Discontinue diroximel fumarate immediately if PML is suspected or if anaphylaxis or angioedema occur Liver function and total bilirubin should be tested prior to initiating diroximel fumarate and during treatment A complete blood count CBC should be obtained prior to starting diroximel fumarate after the first 6 months of administration and at subsequent intervals of 6 to 12 months following this period Suspend treatment if lymphocyte counts are measured to be less than 0 5 109 L for more than 6 months L9623",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB12978",
                        "description": "Diroximel fumarate may increase the hepatotoxic activities of Pexidartinib"
                    },
                    {
                        "drugbank-id": "DB08908",
                        "description": "The serum concentration of Monomethyl fumarate an active metabolite of Diroximel fumarate can be increased when used in combination with Dimethyl fumarate"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}